Mihael Hristos Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. This trade represents a 0.43 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Tuesday, February 25th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average cost of $4.46 per share, with a total value of $44,600.00.

Vanda Pharmaceuticals Stock Up 1.3 %

Shares of Vanda Pharmaceuticals stock opened at $4.76 on Friday. The stock has a market capitalization of $277.58 million, a P/E ratio of -14.88 and a beta of 0.74. The company has a 50-day simple moving average of $4.59 and a 200 day simple moving average of $4.79. Vanda Pharmaceuticals Inc. has a 12-month low of $3.71 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. On average, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VNDA. HC Wainwright raised their price objective on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating for the company.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantinno Capital Management LP acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $48,000. China Universal Asset Management Co. Ltd. increased its position in Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $69,000. Zacks Investment Management acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $74,000. Finally, Intech Investment Management LLC acquired a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at about $84,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.